Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2015

01-05-2015 | Leukemia (A Aguayo, Section Editor)

Thrombosis in Leukemia: Incidence, Causes, and Practical Management

Authors: Patricia Guzmán-Uribe, Ángel Gabriel Vargas-Ruíz

Published in: Current Oncology Reports | Issue 5/2015

Login to get access

Abstract

In patients with acute leukemia (AL), coagulation disorders, which include both thrombotic and hemorrhagic events, are part of the clinical spectrum both at diagnosis and during its evolution. The incidence of these events has been reported by several authors in the range of 1–36 %. This heterogeneity appears to be related to the type of patients included, the study design, and patient-related factors as well as the treatment used. The pathophysiology of thrombosis in AL is complex and multifactorial and includes a myriad of factors that contribute to cancer procoagulant state: synthesis of procoagulant factors by circulating blasts, cellular microparticles, use of endovascular devices (catheters), type of chemotherapy used (l-asparaginase) to name a few. Currently, treatment relies in the use of heparin, followed by vitamin K antagonists for 3 to 6 months. However, randomized controlled studies are required in patients with AL and thrombosis to confirm its safety, duration, and effectiveness.
Literature
1.
2.
Timp JF, Braejjan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–23.CrossRefPubMed
3.•
Colombo R, Gallipoli P, Castelli R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk. 2014; Article in press. A recent review of epidemiology, pathogenesis, prevention and treatment of thrombotic complications in several hematologic malignancies including acute leukemias.
4.
Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res. 2013;131:S59–62.CrossRefPubMed
5.
6.
Guzmán-Uribe P, Rosas-López A, Zepeda-León J, et al. Incidence of thrombosis in adults with acute leukemia: a single center experience in Mexico. Rev Investig Clin. 2013;65:130–40.
7.•
Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol. 2012;24:702–10. This is an excellent review that focuses in venous thromboembolism in different hematological malignances, and highlights the need to create specific treatment guidelines and recommendations for this group of patients.CrossRefPubMed
8.
Crespo-Solis E. Thrombosis in acute leukemia. Hematology. 2012;17:S169–73.PubMed
9.
Wun T, White RH. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thromb Res. 2010;125:S96–102.CrossRefPubMed
10.
Ku GH, White RH, Chew HK, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors and effect on survival. Blood. 2009;113:3911–7.CrossRefPubMedCentralPubMed
11.
Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452–9.CrossRefPubMed
12.
Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia. 2013;27:553–9.CrossRefPubMed
13.•
De Stefano V, Za T, Ciminello A, et al. Haemostatic alterations induced by treatment with asparaginases and clinical consequences. Thromb Haemost 2015; 113. Published ahead of print. Great review about the role of L-asparaginase in the genesis of hemostatic alterations and thrombotic complications.
14.
Ranta S, Tuckuviene R, Mäkipernaa A, et al. Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia—a multicentre study from the Nordic Society of Pediatric Haematology and Oncology. Br J Haematol. 2014; published ahead of print.
15.
Breccia M, Lo CF. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thromb Res. 2014;133:S112–6.CrossRefPubMed
16.
Breccia M, Avvisati G, Latagliata R, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia. 2007;21:79–83.CrossRefPubMed
17.
Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res. 2012;129:S132–6.CrossRefPubMed
18.
Van Aalderen MC, Trappenburg MC, Van Schilfgaarde M, et al. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost. 2011;9:223–6.CrossRefPubMed
19.
Guibo M, Fang L, Linlin LV, et al. Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol. 2013;92:645–52.CrossRef
20.
Kwaan HC, Cull E. The coagulopathy in acute promyelocytic leukemia—what have we learned in the past twenty years. Best Pract Res Clin Hematol. 2014;27:11–8.CrossRef
21.
22.
Johansson E, Hammarskjöld F, Lundberg D, et al. Advantages and disadvantages of peripherally inserted central venous catheters (PICC) compared to other central venous lines: a systematic review of the literature. Acta Oncol. 2013;52:886–92.CrossRefPubMed
23.
Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet. 2013;382:311–25.CrossRefPubMed
24.
Boles JC, Williams JC, Hollinsgsworth RM, et al. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res. 2012;129:197–203.CrossRefPubMed
25.
Montesinos P, DIS J, Vellenga E, et al. Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA 96 and LPA 99 protocols. Blood. 2011;108:1503.
26.
Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the PETHEMA group and review of the literature. Mediterr J Hematol Infect Dis. 2011;3:e2011059.CrossRefPubMedCentralPubMed
27.
Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem. 1999;274(33):23111–8.CrossRefPubMed
28.
Morel O, Morel N, Jesel L, et al. Microparticles: a critical component in the nexus between inflammation, immunity and thrombosis. Semin Immunopathol. 2011;33:469–86.CrossRefPubMed
29.
Koch A, Meesters MI, Scheller B, et al. Systemic endotoxin activity correlates with clot formation: an observational study in patients with early systemic inflammation and sepsis. Crit Care. 2013;17:R198.CrossRefPubMedCentralPubMed
30.
Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med. 2013;137:1286–95.CrossRefPubMed
31.
Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy associated thrombosis. Blood. 2008;111:4902–7.CrossRefPubMedCentralPubMed
32.
Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063–9.CrossRefPubMed
33.
Cortelezzi A, Moia M, Falanga A, et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol. 2005;129:811–7.CrossRefPubMed
34.
Lauw MN, Van der Holt B, Middeldorp S, et al. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation. Thromb Haemost. 2013;109:633–42.CrossRefPubMed
35.
Hunault-Berger M, Chevallier Delain M, Bulabois CE, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93:1488–94.CrossRefPubMed
36.•
Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70. These are the current guidelines to treat patients with cancer and thrombotic complications.CrossRefPubMed
37.
Lee AY, Levine MN, Baker RI, et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53.CrossRefPubMed
38.
Rickles FR, Falanga A, Montesinos P, et al. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res. 2007;120 Suppl 2:S99–106.CrossRefPubMed
39.•
Debordeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013;11:71–80. These are the current guidelines for the treatment and prevention of thrombotic events in patients with cancer and central venous catheters.CrossRef
Metadata
Title
Thrombosis in Leukemia: Incidence, Causes, and Practical Management
Authors
Patricia Guzmán-Uribe
Ángel Gabriel Vargas-Ruíz
Publication date
01-05-2015
Publisher
Springer US
Published in
Current Oncology Reports / Issue 5/2015
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-015-0444-2

Other articles of this Issue 5/2015

Current Oncology Reports 5/2015 Go to the issue

Integrative Care (C Lammersfeld, Section Editor)

Effects of Complementary and Integrative Medicine on Cancer Survivorship

Palliative Medicine (A Jatoi, Section Editor)

The Five Steps of Comprehensive Psychosocial Distress Screening

Gynecologic Cancers (NS Reed, Section Editor)

Review of Neoadjuvant Chemotherapy and Trachelectomy: Which Cervical Cancer Patients Would Be Suitable for Neoadjuvant Chemotherapy Followed by Fertility-Sparing Surgery?

Breast Cancer (B Overmoyer, Section Editor)

Targeting Breast Cancer with CDK Inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits